MedWatch

Lundbeck CEO considers stepping up marketing of Vyepti

The launch of migraine drug Vyepti has not gone well, meaning more will potentially be invested in the commercial apparatus behind the treatment.

Photo: Gregers Tycho/ERH

Migraine drug Vyepti was launched in the US in April 2020, and thanks to the Covid-19 crisis, this did not go well. CEO at Lundbeck Deborah Dunsire thinks the drug has the potential to become a blockbuster, but that requires a boost to the marketing of the drug, Danish financial daily Børsen reports.

"With the growth in the migraine market and the market for cluster headaches, which often follow, and the potential for other indications, Vyepti will be a blockbuster drug in the mid-2030s, right before the patent expires. I am 100 percent sure of that," Dunsire says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs